Our Offerings
By Industry By Function
About Us
Our Viewpoint
NEW
 Senior Management Experts Panel Global Consultants Press Releases Blog
Infographics Market Insights Case Studies Illustrations In The Press
Contact Us
The Business Research Company Logo
Reports Store
Top 50 Healthcare Market Reports
NEW
 Top 50 Non-Healthcare Market Reports
NEW
 Opportunities And Strategies Reports Aerospace And Defense Agriculture Chemicals Construction
Electrical And Electronics Financial Services Food And Beverages Healthcare Services Hospitality Information Technology Machinery Media
Medical Equipment Metal And Mineral Mining Oil And Gas Paper, Plastics, Rubber, Wood And Textile Pharmaceuticals Professional Services Recreation
Retail And Wholesale Services Social Services Transport Transport Services Utilities Veterinary Healthcare Filter Reports by Trends
NEW
Market Intelligence Platform
About GMM Global Forecast
NEW
 Mega Trends Analysis
Consultancies Corporate Planning & Strategy Academic Financial Services Legal Services
Pricing Methodology Sources FAQ Press Coverage
Customized Research
Find Customers Optimise Your Marketing Mix Evaluate Competitors Identify Market Opportunities Develop Products And Services
Distributor And Partner Research Plan Finances Streamline Your Operations Devise Market Entry Strategy Explore Custom Research Packages
NEW
Continuous Research
Desk Research Research Reports Senior Executive Interviews Consumer Research Market Sizing And Forecasts
Company Information Analytics And Data Visualization Research Automation Web Crawling And Spidering AI-Empowered Research Services
Request Proposal
Non-Small Cell Lung Cancer (NSCLC) Global Market Opportunities And Strategies To 2034

Wait, we have a special offer for you! ✋

Get your exclusive 20% discount only on the Global Market Reports now using the code ONLINE20*

YES, get the discount! No, I'd pay the full price

*Copy paste the discount code in the cart

Non-Small Cell Lung Cancer (NSCLC) Global Market Opportunities And Strategies To 2034

Non-Small Cell Lung Cancer NSCLC Market 2025 - By Type (Squamous Cell Carcinoma, Large Cell Carcinoma, Adenocarcinoma, Other Types), By Therapy (Radiation Therapy, Chemotherapy, Targeted Therapy, Immunotherapy, Other Therapies), By Distribution Channel (Hospital Pharmacy, Online Pharmacy, Other Distribution Channels), And By Region, Opportunities And Strategies – Global Forecast To 2035

Non-Small Cell Lung Cancer NSCLC Market 2025

Report Price : $4490.00 | Pages : 121 | Published : November 2025 | Delivery Time: Immediately Info icon | Format : pdf icon

Purchase Options
Request a Sample
Request For Discount
Customise Your Report
Item added to cart!
Request For Regional Data
Non-Small Cell Lung Cancer (NSCLC) Global Market Opportunities And Strategies To 2034
Description Table Of Contents Tables & Figures

Market Insights

Related Reports

Non-Small Cell Lung Cancer (NSCLC)Market Definition

Non-small cell lung cancer (NSCLC) refers to a group of lung cancers that behave and respond to treatment differently than small cell lung cancer. It includes several histological subtypes such as adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. NSCLC typically grows and spreads more slowly than small cell lung cancer (SCLC).

The non-small cell lung cancer (NSCLC) market consists of revenues generated by entities that develop and provide therapeutics, diagnostics, and treatment services targeted at NSCLC patients. These services and products are used primarily in hospital settings, cancer specialty centers, outpatient oncology clinics, and sometimes in home care environments.

Non-Small Cell Lung Cancer (NSCLC) Global Market Opportunities And Strategies To 2034 Market Size and growth rate 2025 to 2029: Graph

Non-Small Cell Lung Cancer (NSCLC)Market Size

The global non-small cell lung cancer (NSCLC) market reached a value of nearly $38,199.05 million in 2024, having grown at a compound annual growth rate (CAGR) of 7.68% since 2019. The market is expected to grow from $38,199.05 million in 2024 to $63,708.97 million in 2029 at a rate of 10.77%. The market is then expected to grow at a CAGR of 10.55% from 2029 and reach $105,206.16 million in 2034.

Growth in the historic period resulted from growing demand for precision medicine, rising prevalence of smoking and air pollution, expansion of clinical trials and rising prevalence of lung cancer. Factors that negatively affected growth in the historic period were high treatment costs and adverse effects of chemotherapy.

Going forward, increasing research and development in healthcare, rise in public awareness campaigns, rise in advancements in targeted therapies and immunotherapies and growing demand for precision medicine will drive growth. Factors that could hinder the growth of the non-small cell lung cancer (NSCLC) market in the future include limited stringent regulatory approvals, impact of trade war and tariffs and limited access in developing regions competition from substitute products and impact of trade war and tariff.  

Non-Small Cell Lung Cancer (NSCLC)Market Drivers

The key drivers of the non-small cell lung cancer (nsclc)market include:

Increasing Research And Development In Healthcare

Increasing research and development in healthcare is expected to propel the growth of the non-small cell lung cancer (NSCLC) market going forward. It leads to the discovery of new targeted therapies, immunotherapies, and precision medicine approaches, which improve patient outcomes. Advanced R&D also accelerates clinical trials and regulatory approvals for novel drugs. As a result, healthcare providers have more effective options.  The increasing research and development in healthcare during the forecast period in 2024 is 2.00%.

Non-Small Cell Lung Cancer (NSCLC)Market Restraints

The key restraints on the non-small cell lung cancer (nsclc)market include:

Stringent Regulatory Approvals

Stringent regulatory approvals are expected to restrain the growth of the non-small cell lung cancer (NSCLC) market during the forecast period by delaying the launch of new therapies and increasing the time and cost required for clinical trials. Companies must comply with rigorous safety, efficacy, and quality standards, which can slow product commercialization. These stringent requirements may also limit the entry of innovative drugs, reducing treatment options for patients.  Growth affected by stringent regulatory approvals during the forecast period in 2024 is -1.45%.

Non-Small Cell Lung Cancer (NSCLC)Market Trends

Major trends shaping the non-small cell lung cancer (nsclc)market include:

Dual-Immune Activation Therapy Shows Promise in Immunotherapy-Resistant NSCLC

Major companies in the non-small cell lung cancer (NSCLC) market are developing dual-immune activation mechanisms to simultaneously target multiple immune pathways, enhancing anti-tumor responses. This approach aims to overcome resistance seen with single-agent immunotherapies and improve long-term survival outcomes in patients. For instance, in August 2025, Innovent Biologics, Inc., a China-based biopharmaceutical company, announces that the U.S. Food and Drug Administration a government department clears its investigational new drug application to initiate a global Phase 3 trial (MarsLight-11) of IBI363 in immunotherapy-resistant squamous non-small cell lung cancer. IBI363, a self-discovered PD-1/IL-2a-bias bispecific antibody fusion protein, has also received Fast Track Designation in the U.S. and Breakthrough Therapy Designation in China.

Rapid 24-Hour Tumor Profiling for Precision NSCLC Treatment

Major companies in the non-small cell lung cancer (NSCLC) market are developing rapid turnaround time tests to enable faster and more accurate tumor profiling, guiding timely treatment decisions. These tests aim to reduce diagnostic delays, improve patient outcomes, and support personalized therapy selection. For instance, in July 2025, Thermo Fisher Scientific, a US-based life science and clinical research company announces that the U.S. Food and Drug Administration (FDA) approves the Oncomine Dx Express Test on the Ion Torrent Genexus Dx Integrated Sequencer as an in vitro diagnostic (IVD) companion diagnostic for Dizal’s ZEGFROVY (sunvozertinib) in patients with non-small cell lung cancer (NSCLC). This NGS assay identifies NSCLC patients harboring estimated glomerular filtration rate (EGFR) exon 20 insertion mutations and supports rapid genomic insights, delivering results in as little as 24 hours to aid precision oncology decisions. The Oncomine Dx Express Test is approved for use on the Ion Torrent Genexus Dx Integrated Sequencer as an in vitro diagnostic (IVD) assay. It serves as a companion diagnostic (CDx) for Dizal’s ZEGFROVY to identify NSCLC patients with EGFR exon 20 insertion mutations.

Opportunities And Recommendations In The Non-small cell lung cancer (NSCLC)Market

Opportunities – The top opportunities in the non-small cell lung cancer (NSCLC) market segmented by type will arise in the adenocarcinoma segment, which will gain $15,119.76 million of global annual sales by 2029. The top opportunities in the non-small cell lung cancer (NSCLC) market segmented by therapy will arise in the immunotherapy segment, which will gain $12,024.80 million of global annual sales by 2029. The top opportunities in the non-small cell lung cancer (NSCLC) market segmented by distribution channel will arise in the hospital pharmacy segment, which will gain $17,589.99 million of global annual sales by 2029. The non-small cell lung cancer (NSCLC) market size will gain the most in the USA at $9,428.79 million.

Recommendations- To take advantage of the opportunities, The Business Research Company recommends the non-small cell lung cancer (NSCLC) companies to focus on integrating augmented reality for enhanced driver experience and safety, focus on advancing dual-immune activation to address therapy resistance in nsclc, focus on accelerating diagnostic solutions to improve treatment timeliness in nsclc, focus on developing oral tyrosine kinase inhibitors to enhance targeted nsclc treatment, focus on advancing mrna-based precision immunotherapy for personalized nsclc treatment, focus on advancing third-generation egfr-tkis to address drug resistance in nsclc, focus on expanding presence in the adenocarcinoma segment to capture high-growth opportunities, focus on expanding in the immunotherapy segment to drive market growth, expand in emerging markets, continue to focus on developed markets, focus on expanding omnichannel distribution to improve market reach , focus on optimizing value-based pricing to enhance market competitiveness, focus on strengthening physician and patient engagement to increase treatment awareness, focus on expanding digital and data-driven marketing to improve reach and efficiency, focus on strengthening presence in the online pharmacy segment to maximize growth.

chesta image

Book your 30 minutes free consultation with our research experts

Contact Us

Non-Small Cell Lung Cancer (NSCLC)Market Segmentation

The non-small cell lung cancer (NSCLC)market is segmented by type, by therapy, and by distribution channel.



By Type –


The Non-small cell lung cancer (NSCLC)market is segmented by type into:

    • a) Squamous Cell Carcinoma

    • b) Large Cell Carcinoma

    • c) Adenocarcinoma

    • d) Other Types

The adenocarcinoma market was the largest segment of the non-small cell lung cancer (NSCLC) market segmented by type, accounting for 44.04% or $16,824.15 million of the total in 2024. Going forward, the adenocarcinoma segment is expected to be the fastest growing segment in the non-small cell lung cancer (NSCLC) market segmented by type, at a CAGR of 13.68% during 2024-2029.



By Therapy –


The Non-small cell lung cancer (NSCLC)market is segmented by therapy into:

    • a) Radiation Therapy

    • b) Chemotherapy

    • b) Targeted Therapy

    • b) Immunotherapy

    • b) Other Therapies

The chemotherapy market was the largest segment of the non-small cell lung cancer (NSCLC) market segmented by therapy, accounting for 30.92% or $11,811.38 million of the total in 2024. Going forward, the immunotherapy segment is expected to be the fastest growing segment in the non-small cell lung cancer (NSCLC) market segmented by therapy, at a CAGR of 20.66% during 2024-2029.



By Distribution Channel –


The Non-small cell lung cancer (NSCLC)market is segmented by distribution channel into:

    • a) Hospital Pharmacy

    • b) Online Pharmacy

    • c) Other Distribution Channels

The hospital pharmacy market was the largest segment of the non-small cell lung cancer (NSCLC) market segmented by distribution channel, accounting for 69.17% or $26,423.28 million of the total in 2024. Going forward, the online pharmacy segment is expected to be the fastest growing segment in the non-small cell lung cancer (NSCLC) market segmented by distribution channel, at a CAGR of 18.64% during 2024-2029.



By Geography - The Non-small cell lung cancer (NSCLC)market is segmented by geography into:

      o Asia Pacific

      • • China

      • • India

      • • Japan

      • • Australia

      • • Indonesia

      • • South Korea

      o North America

      • • USA

      • • Canada

      o South America

      • • Brazil

      o Western Europe

      • • France

      • • Germany

      • • UK

      • • Italy

      • • Spain

      o Eastern Europe

      • • Russia

      o Middle East

      o Africa

North America was the largest region in the non-small cell lung cancer (NSCLC) market, accounting for 43.66% or $16,677.81 million of the total in 2024. It was followed by Asia-Pacific, Western Europe and then the other regions. Going forward, the fastest-growing regions in the non-small cell lung cancer (NSCLC) market will be Asia-Pacific and Africa where growth will be at CAGRs of 12.49% and 12.02% respectively. These will be followed by Middle East and Eastern Europe where the markets are expected to grow at CAGRs of 11.64% and 10.43% respectively.

Non-Small Cell Lung Cancer (NSCLC) Market Competitive Landscape

Major Competitors are:

  • Merck & Co., Inc.

  • AstraZeneca

  • Bristol-Myers Squibb Company

  • F. Hoffmann-La Roche AG

  • Pfizer Inc.

    • Other Competitors Include:

  • Eli Lilly and Company

  • Regeneron Pharmaceuticals Inc.

  • Amgen Inc.

  • Novartis AG

  • Takeda Pharmaceutical Company Limited

  • Hansoh Pharmaceutical Group Co., Ltd

  • Dizal (Jiangsu) Pharmaceutical Co Ltd

  • HUTCHMED

  • GlaxoSmithKline

  • Akeso, Inc.

  • Immutep Ltd

  • Sanofi

  • AbbVie

  • Daiichi Sankyo Company

  • Johnson & Johnson

  • Yuhan Corporation

  • Samsung Medical Center

  • ONO Pharmaceutical Co., Ltd.

  • Glenmark Pharmaceuticals Ltd

  • PT Etana Biotechnologies Indonesia

  • Hikma Pharmaceuticals PLC

  • Zydus Lifesciences Limited

  • Clovis Oncology Germany Gmbh

  • PDC*line Pharma

  • Bayer Global

  • OSE Immunotherapeutics

  • BioNTech SE

  • iOnctura SA

  • Summit Therapeutics Inc

  • SOTIO

  • BIOCAD

  • Viatris Inc

  • Amneal Pharmaceuticals LLC

  • Revolution Medicines

  • Apollomics Inc

  • Tempus

  • Novartis Pharmaceuticals Canada Inc.

  • Nuvalent

  • Illumina

  • Qiagen

  • sehamed global ltd

  • GE Healthcare Technologies Inc

  • Diatech Pharmacogenetics S.R.L

  • SEDICO Pharmaceutical Industries

  • EIPICO (Egyptian International Pharmaceutical Industries Co.)

  • Aspen Pharmacare Nigeria Ltd

  • Adcock Ingram

  • Pharco Pharmaceuticals

    • Author: Abdul Wasay

      Table Of Contents

      1 Executive Summary

      1.1 Non-Small Cell Lung Cancer (NSCLC) – Market Attractiveness And Macro Economic Landscape

      2 Table Of Contents

      3 List Of Tables

      4 List Of Figures

      5 Report Structure

      6 Market Characteristics

      6.1 General Market Definition

      6.2 Summary

      6.3 Non-Small Cell Lung Cancer (NSCLC) Market Definition And Segmentations

      6.4 Market Segmentation By Type

      6.4.1 Squamous Cell Carcinoma

      6.4.2 Large Cell Carcinoma

      6.4.3 Adenocarcinoma

      6.4.4 Other Types

      6.5 Market Segmentation By Therapy

      6.5.1 Radiation Therapy

      6.5.2 Chemotherapy

      6.5.3 Targeted therapy

      6.5.4 Immunotherapy

      6.5.5 Other Therapies

      6.6 Market Segmentation By Distribution Channel

      6.6.1 Hospital Pharmacy

      6.6.2 Online Pharmacy

      6.6.3 Other Distribution Channels

      7 Major Market Trends

      7.1 Bromodomain Inhibitor Gains Fast Track Designations for Resistant Non-Small Cell Lung Cancer

      7.2 Dual-Immune Activation Therapy Shows Promise in Immunotherapy-Resistant NSCLC

      7.3 Rapid 24-Hour Tumor Profiling for Precision NSCLC Treatment

      7.4 Oral Tyrosine Kinase Inhibitors Accelerate Targeted NSCLC Treatment Advances

      7.5 FDA Clears Investigational mRNA-Based Precision Immunotherapy

      7.6 Third-Generation EGFR-TKI Gains Approval for Stage III NSCLC Maintenance Therapy

      8 Global Non-Small Cell Lung Cancer (NSCLC) Growth Analysis And Strategic Analysis Framework

      8.1 Global Non-Small Cell Lung Cancer (NSCLC) PESTEL Analysis

      8.1.1 Political

      8.1.2 Economic

      8.1.3 Social

      8.1.4 Technological

      8.1.5 Environmental

      8.1.6 Legal

      8.2 Analysis Of End Users (B2B)

      8.2.1 Hospitals

      8.2.2 Specialty Clinics

      8.2.3 Homecare

      8.2.4 Research Institutes

      8.2.5 Other End Users

      8.3 Global Non-Small Cell Lung Cancer (NSCLC) Market Growth Rate Analysis

      8.4 Historic Market Growth, 2019 – 2024, Value ($ Million)

      8.4.1 Market Drivers 2019 – 2024

      8.4.2 Market Restraints 2019– 2024

      8.5 Forecast Market Growth, 2024 – 2029, 2034F Value ($ Million)

      8.6 Forecast Growth Contributors/Factors

      8.6.1 Quantitative Growth Contributors

      8.6.2 Drivers

      8.6.3 Restraints

      8.7 Global Non-Small Cell Lung Cancer (NSCLC) Total Addressable Market (TAM)

      9 Global Non-Small Cell Lung Cancer (NSCLC) Market Segmentation

      9.1 Global Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      9.2 Global Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      9.3 Global Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      9.4 Global Non-Small Cell Lung Cancer (NSCLC) Market, Sub-Segmentation Of Squamous Cell Carcinoma, By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      9.5 Global Non-Small Cell Lung Cancer (NSCLC) Market, Sub-Segmentation Of Large Cell Carcinoma, By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      9.6 Global Non-Small Cell Lung Cancer (NSCLC) Market, Sub-Segmentation Of Adenocarcinoma, By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      9.7 Global Non-Small Cell Lung Cancer (NSCLC) Market, Sub-Segmentation Of Other Types, By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      10 Non-Small Cell Lung Cancer (NSCLC) Market, Regional and Country Analysis

      10.1 Global Non-Small Cell Lung Cancer (NSCLC) Market, By Region, Historic and Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      10.2 Global Non-Small Cell Lung Cancer (NSCLC) Market, By Country, Historic and Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      11 Asia-Pacific Market

      11.1 Summary

      11.2 Market Overview

      11.2.1 Region Information

      11.2.2 Market Information

      11.2.3 Background Information

      11.2.4 Government Initiatives

      11.2.5 Regulations

      11.2.6 Regulatory Bodies

      11.2.7 Major Associations

      11.2.8 Taxes Levied

      11.2.9 Corporate Tax Structure

      11.2.10 Investments

      11.2.11 Major Companies

      11.3 Asia-Pacific Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      11.4 Asia-Pacific Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      11.5 Asia-Pacific Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      11.6 Asia-Pacific Non-Small Cell Lung Cancer (NSCLC) Market: Country Analysis

      11.7 China Market

      11.8 Summary

      11.9 Market Overview

      11.9.1 Country Information

      11.9.2 Market Information

      11.9.3 Background Information

      11.9.4 Government Initiatives

      11.9.5 Regulations

      11.9.6 Regulatory Bodies

      11.9.7 Major Associations

      11.9.8 Taxes Levied

      11.9.9 Corporate Tax Structure

      11.9.10 Investments

      11.9.11 Major Companies

      11.10 China Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      11.11 China Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      11.12 China Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      11.13 India Market

      11.14 India Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      11.15 India Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      11.16 India Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      11.17 Japan Market

      11.18 Summary

      11.19 Market Overview

      11.19.1 Country Information

      11.19.2 Market Information

      11.19.3 Background Information

      11.19.4 Government Initiatives

      11.19.5 Regulations

      11.19.6 Regulatory Bodies

      11.19.7 Major Associations

      11.19.8 Taxes Levied

      11.19.9 Corporate Tax Structure

      11.19.10 Investments

      11.19.11 Major Companies

      11.20 Japan Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      11.21 Japan Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      11.22 Japan Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      11.23 South Korea Market

      11.24 Summary

      11.25 Market Overview

      11.25.1 Country Information

      11.25.2 Market Information

      11.25.3 Background Information

      11.25.4 Government Initiatives

      11.25.5 Regulations

      11.25.6 Regulatory Bodies

      11.25.7 Major Associations

      11.25.8 Taxes Levied

      11.25.9 Corporate Tax Structure

      11.25.10 Investments

      11.25.11 Major Companies

      11.26 South Korea Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      11.27 South Korea Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      11.28 South Korea Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      11.29 Australia Market

      11.30 Australia Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      11.31 Australia Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      11.32 Australia Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      11.33 Indonesia Market

      11.34 Indonesia Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      11.35 Indonesia Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      11.36 Indonesia Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      12 Western Europe Market

      12.1 Summary

      12.2 Market Overview

      12.2.1 Region Information

      12.2.2 Market Information

      12.2.3 Background Information

      12.2.4 Government Initiatives

      12.2.5 Regulations

      12.2.6 Regulatory Bodies

      12.2.7 Major Associations

      12.2.8 Taxes Levied

      12.2.9 Corporate tax structure

      12.2.10 Investments

      12.2.11 Major Companies

      12.3 Western Europe Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      12.4 Western Europe Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      12.5 Western Europe Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      12.6 Western Europe Non-Small Cell Lung Cancer (NSCLC) Market: Country Analysis

      12.7 UK Market

      12.8 UK Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      12.9 UK Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      12.10 UK Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      12.11 Germany Market

      12.12 Germany Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      12.13 Germany Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      12.14 Germany Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      12.15 France Market

      12.16 France Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      12.17 France Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      12.18 France Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      12.19 Italy Market

      12.20 Italy Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      12.21 Italy Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      12.22 Italy Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      12.23 Spain Market

      12.24 Spain Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      12.25 Spain Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      12.26 Spain Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      13 Eastern Europe Market

      13.1 Summary

      13.2 Market Overview

      13.2.1 Region Information

      13.2.2 Market Information

      13.2.3 Background Information

      13.2.4 Government Initiatives

      13.2.5 Regulations

      13.2.6 Regulatory Bodies

      13.2.7 Major Associations

      13.2.8 Taxes Levied

      13.2.9 Corporate Tax Structure

      13.2.10 Major companies

      13.3 Eastern Europe Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      13.4 Eastern Europe Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      13.5 Eastern Europe Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      13.6 Russia Market

      13.7 Russia Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      13.8 Russia Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      13.9 Russia Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      14 North America Market

      14.1 Summary

      14.2 Market Overview

      14.2.1 Region Information

      14.2.2 Market Information

      14.2.3 Background Information

      14.2.4 Government Initiatives

      14.2.5 Regulations

      14.2.6 Regulatory Bodies

      14.2.7 Major Associations

      14.2.8 Taxes Levied

      14.2.9 Corporate Tax Structure

      14.2.10 Investments

      14.2.11 Major Companies

      14.3 North America Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      14.4 North America Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      14.5 North America Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      14.6 North America Non-Small Cell Lung Cancer (NSCLC) Market: Country Analysis

      14.7 USA Market

      14.8 Summary

      14.9 Market Overview

      14.9.1 Country Information

      14.9.2 Market Information

      14.9.3 Background Information

      14.9.4 Government Initiatives

      14.9.5 Regulations

      14.9.6 Regulatory Bodies

      14.9.7 Major Associations

      14.9.8 Taxes Levied

      14.9.9 Corporate Tax Structure

      14.9.10 Investments

      14.9.11 Major Companies

      14.10 USA Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      14.11 USA Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      14.12 USA Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      14.13 Canada Market

      14.14 Summary

      14.15 Market Overview

      14.15.1 Country Information

      14.15.2 Market Information

      14.15.3 Background Information

      14.15.4 Government Initiatives

      14.15.5 Regulations

      14.15.6 Regulatory Bodies

      14.15.7 Major Associations

      14.15.8 Taxes Levied

      14.15.9 Corporate Tax Structure

      14.15.10 Investments

      14.15.11 Major Companies

      14.16 Canada Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      14.17 Canada Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      14.18 Canada Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      15 South America Market

      15.1 Summary

      15.2 Market Overview

      15.2.1 Region Information

      15.2.2 Market Information

      15.2.3 Background Information

      15.2.4 Government Initiatives

      15.2.5 Regulations

      15.2.6 Regulatory Bodies

      15.2.7 Major Associations

      15.2.8 Taxes Levied

      15.2.9 Corporate Tax Structure

      15.2.10 Major Companies

      15.3 South America Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      15.4 South America Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      15.5 South America Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      15.6 Brazil Market

      15.7 Brazil Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      15.8 Brazil Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      15.9 Brazil Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      16 Middle East Market

      16.1 Summary

      16.2 Market Overview

      16.2.1 Region Information

      16.2.2 Market Information

      16.2.3 Background Information

      16.2.4 Government Initiatives

      16.2.5 Regulations

      16.2.6 Regulatory Bodies

      16.2.7 Major Associations

      16.2.8 Taxes Levied

      16.2.9 Corporate Tax Structure

      16.2.10 Major Companies

      16.3 Middle East Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      16.4 Middle East Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      16.5 Middle East Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      17 Africa Market

      17.1 Summary

      17.2 Market Overview

      17.2.1 Region Information

      17.2.2 Market Information

      17.2.3 Background Information

      17.2.4 Government Initiatives

      17.2.5 Regulations

      17.2.6 Regulatory Bodies

      17.2.7 Major Associations

      17.2.8 Taxes Levied

      17.2.9 Corporate Tax Structure

      17.2.10 Major Companies

      17.3 Africa Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      17.4 Africa Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      17.5 Africa Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      18 Competitive Landscape And Company Profiles

      18.1      Company Profiles

      18.2 Merck & Co., Inc

      18.2.1 Company Overview

      18.2.2 Products And Services

      18.2.3 Business Strategy

      18.2.4 Financial Overview

      18.3 AstraZeneca plc

      18.3.1 Company Overview

      18.3.2 Products And Services

      18.3.3 Business Strategy

      18.3.4 Financial Overview

      18.4 Bristol Myers Squibb Company

      18.4.1 Company Overview

      18.4.2 Products And Services

      18.4.3 Business Strategy

      18.4.4 Financial Overview

      18.5 F. Hoffman-La Roche Ltd

      18.5.1 Company Overview

      18.5.2 Products And Services

      18.5.3 Business Strategy

      18.5.4 Financial Overview

      18.6 Pfizer Inc

      18.6.1 Company Overview

      18.6.2 Products And Services

      18.6.3 Business Strategy

      18.6.4 Financial Overview

      19 Other Major And Innovative Companies

      19.1 Eli Lilly and Company

      19.1.1 Company Overview

      19.1.2 Products And Services

      19.2 Regeneron Pharmaceuticals Inc.

      19.2.1 Company Overview

      19.2.2 Products And Services

      19.3 Amgen Inc.

      19.3.1 Company Overview

      19.3.2 Products And Services

      19.4 Novartis AG

      19.4.1 Company Overview

      19.4.2 Products And Services

      19.5 Takeda Pharmaceutical Company Limited

      19.5.1 Company Overview

      19.5.2 Products And Services

      19.6 Janssen Biotech, Inc.

      19.6.1 Company Overview

      19.6.2 Products And Services

      19.7 Rigel Pharmaceuticals, Inc.

      19.7.1 Company Overview

      19.7.2 Products And Services

      19.8 Partner Therapeutics/Merus N.V.

      19.8.1 Company Overview

      19.8.2 Products And Services

      19.9 AbbVie Inc.

      19.9.1 Company Overview

      19.9.2 Products And Services

      19.10 Nuvation Bio

      19.10.1 Company Overview

      19.10.2 Products And Services

      19.11 Iovance Biotherapeutics

      19.11.1 Company Overview

      19.11.2 Products And Services

      19.12 Dizal Pharmaceutical

      19.12.1 Company Overview

      19.12.2 Products And Services

      19.13 Daiichi Sankyo / AZ

      19.13.1 Company Overview

      19.13.2 Products And Services

      19.14 Xcovery Holdings, Inc.

      19.14.1 Company Overview

      19.14.2 Products And Services

      19.15 Boehringer Ingelheim

      19.15.1 Company Overview

      19.15.2 Products And Services

      20 Competitive Benchmarking

      21 Competitive Dashboard

      22 Key Mergers And Acquisitions

      22.1 Bristol Myers Squibb Expands Oncology Reach WITH $4.8b Mirati Therapeutics Acquisition

      22.2 Pierre Fabre Acquires Vertical Bio To Advance Novel NSCLC Therapy Pipeline

      22.3 Bristol Myers Squibb Expands Precision Oncology With $4.1b Turning Point Therapeutics Acquisition

      23 Recent Developments In The Non-small Cell Lung Cancer (NSCLC) Market

      23.1 First-In-Class PD-1/VEGF Bispecific Antibody Wins Approval For Frontline Lung Cancer Treatment

      23.2 FDA Approves Optune Lua Combination Therapy for Advanced Lung Cancer Patients

      24 Opportunities And Strategies

      24.1 Global Non-Small Cell Lung Cancer (NSCLC) Market In 2029 – Countries Offering Most New Opportunities

      24.2 Global Non-Small Cell Lung Cancer (NSCLC) Market In 2029 – Segments Offering Most New Opportunities

      24.3 Global Non-Small Cell Lung Cancer (NSCLC) Market In 2029 – Growth Strategies

      24.3.1 Market Trend Based Strategies

      24.3.2 Competitor Strategies

      25 Non-Small Cell Lung Cancer (NSCLC) Market, Conclusions And Recommendations

      25.1 Conclusions

      25.2 Recommendations

      25.2.1 Product

      25.2.2 Place

      25.2.3 Price

      25.2.4 Promotion

      25.2.5 People

      26 Appendix

      26.1 Geographies Covered

      26.2 Market Data Sources

      26.3 Research Methodology

      26.4 Currencies

      26.5 The Business Research Company

      26.6 Copyright and Disclaimer

    List Of Tables

      Table 1: Global Non-Small Cell Lung Cancer (NSCLC) Market, Historic, 2019 – 2024, $ Million
    • Table 2: Global Non-Small Cell Lung Cancer (NSCLC) Market, Forecast, 2024 – 2029, 2034F, $ Million
    • Table 3: Global Non-Small Cell Lung Cancer (NSCLC) Market TAM, 2024 And 2034, $ Million
    • Table 4: Global Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 5: Global Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 6: Global Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 7: Global Non-Small Cell Lung Cancer (NSCLC) Market, Sub-Segmentation Of Squamous Cell Carcinoma, By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 8: Global Non-Small Cell Lung Cancer (NSCLC) Market, Sub-Segmentation Of Large Cell Carcinoma, By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 9: Global Non-Small Cell Lung Cancer (NSCLC) Market, Sub-Segmentation Of Adenocarcinoma, By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 10: Global Non-Small Cell Lung Cancer (NSCLC) Market, Sub-Segmentation Of Other Types, By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 11: Global Non-Small Cell Lung Cancer (NSCLC) Market, By Region, Historic and Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 12: Global Non-Small Cell Lung Cancer (NSCLC) Market, By Country, Historic and Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 13: Asia-Pacific GDP Per Capita, By Country, 2019-2024, $
    • Table 14:  Asia-Pacific Population, By Country, 2019-2029, Millions
    • Table 15: Asia-Pacific Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 16: Asia-Pacific Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 17: Asia-Pacific Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 18: China GDP Per Capita, 2019-2024, $
    • Table 19:  China Population, 2019-2029, Millions
    • Table 20: China Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 21: China Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 22: China Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 23: India Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 24: India Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 25: India Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 26: Japan GDP Per Capita, 2019-2024, $
    • Table 27:  Japan Population, 2019-2029, Millions
    • Table 28: Japan Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 29: Japan Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 30: Japan Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 31: South Korea GDP Per Capita, 2019-2024, $
    • Table 32:  South Korea Population, 2019-2029, Millions
    • Table 33: South Korea Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 34: South Korea Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 35: South Korea Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 36: Australia Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 37: Australia Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 38: Australia Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 39: Indonesia Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 40: Indonesia Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 41: Indonesia Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 42: Western Europe GDP Per Capita, By Country, 2019-2024, $
    • Table 43:  Western Europe Population, By Country, 2019-2029, Millions
    • Table 44: Western Europe Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 45: Western Europe Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 46: Western Europe Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 47: UK Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 48: UK Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 49: UK Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 50: Germany Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 51: Germany Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 52: Germany Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 53: France Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 54: France Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 55: France Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 56: Italy Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 57: Italy Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 58: Italy Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 59: Spain Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 60: Spain Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 61: Spain Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 62: Eastern Europe GDP Per Capita, By Country, 2019-2024, $
    • Table 63:  Eastern Europe Population, By Country, 2019-2029, Millions
    • Table 64: Eastern Europe Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 65: Eastern Europe Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 66: Eastern Europe Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 67: Russia Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 68: Russia Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 69: Russia Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 70: North America GDP Per Capita, By Country, 2019-2024, $
    • Table 71:  North America Population, By Country, 2019-2029, Millions
    • Table 72: North America Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 73: North America Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 74: North America Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 75: USA GDP Per Capita, 2019-2024, $
    • Table 76:  USA Population, 2019-2029, Millions
    • Table 77: USA Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 78: USA Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 79: USA Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 80: Canada GDP Per Capita, 2019-2024, $
    • Table 81:  Canada Population, 2019-2029, Millions
    • Table 82: Canada Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 83: Canada Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 84: Canada Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 85: South America GDP Per Capita, By Country, 2019-2024, $
    • Table 86:  South America Population, By Country, 2019-2029, Millions
    • Table 87: South America Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 88: South America Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 89: South America Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 90: Brazil Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 91: Brazil Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 92: Brazil Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 93: Middle East GDP Per Capita, By Country, 2019-2024, $
    • Table 94:  Middle East Population, By Country, 2019-2029, Millions
    • Table 95: Middle East Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 96: Middle East Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 97: Middle East Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 98: Africa GDP Per Capita, By Country, 2019-2024, $
    • Table 99:  Africa Population, By Country, 2019-2029, Millions
    • Table 100: Africa Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 101: Africa Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 102: Africa Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 103: Global Non-Small Cell Lung Cancer (NSCLC) Market, Key Competitor Estimated Market Shares, 2024, Percentage (%)
    • Table 104: Merck & Co., Inc – Financial Overview, 2020 – 2024, $Billion
    • Table 105: AstraZeneca plc – Financial Overview, 2020 – 2024, $Billion
    • Table 106: Bristol-Myers Squibb Company – Financial Overview, 2020 – 2024, $ Billion
    • Table 107: F. Hoffmann-La Roche Ltd – Financial Overview, 2020 – 2024, $Billion
    • Table 108: Pfizer Inc – Financial Overview, 2020 – 2024, $Billion
    • Table 109:  Non-Small Cell Lung Cancer (NSCLC) Market, Competitive Benchmarking (In USD Millions)
    • Table 110:  Non-Small Cell Lung Cancer (NSCLC) Market, Competitive Dashboard
    • Table 111: Global Non-Small Cell Lung Cancer (NSCLC) Market Size Gain ($ Million), 2024 – 2029, By Country
    • Table 112: Global Non-Small Cell Lung Cancer (NSCLC) Market Size Gain ($ Million), Segmentation By Type, 2024 – 2029
    • Table 113: Global Non-Small Cell Lung Cancer (NSCLC) Market Size Gain ($ Million), Segmentation By Therapy, 2024 – 2029
    • Table 114: Global Non-Small Cell Lung Cancer (NSCLC) Market Size Gain ($ Million), Segmentation By Distribution Channel, 2024 – 2029
    • Table 115: Non-Small Cell Lung Cancer (NSCLC) Market Data Sources

    List Of Figures

      Figure 1: Global Non-Small Cell Lung Cancer (NSCLC) Market Segmentation By Type
    • Figure 2: Global Non-Small Cell Lung Cancer (NSCLC) Market Segmentation By Therapy
    • Figure 3: Global Non-Small Cell Lung Cancer (NSCLC) Market Segmentation By Distribution Channel
    • Figure 4: Global Non-Small Cell Lung Cancer (NSCLC) Market, PESTEL (Political, Economic, Social, Technology, Environmental and Legal) Analysis
    • Figure 5: Global Non-Small Cell Lung Cancer (NSCLC) Market, Historic, 2019 – 2024, $ Million
    • Figure 6: Global Non-Small Cell Lung Cancer (NSCLC) Market, Forecast, 2024 – 2029, 2034F, $ Million
    • Figure 7: Global Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 8: Global Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 9: Global Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 10: Global Non-Small Cell Lung Cancer (NSCLC) Market, Sub-Segmentation Of Squamous Cell Carcinoma, By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 11: Global Non-Small Cell Lung Cancer (NSCLC) Market, Sub-Segmentation Of Large Cell Carcinoma, By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 12: Global Non-Small Cell Lung Cancer (NSCLC) Market, Sub-Segmentation Of Adenocarcinoma, By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 13: Global Non-Small Cell Lung Cancer (NSCLC) Market, Sub-Segmentation Of Other Types, By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 14: Global Non-Small Cell Lung Cancer (NSCLC) Market, By Region, Historic and Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 15: Global Non-Small Cell Lung Cancer (NSCLC) Market, By Country, Historic and Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 16: Asia-Pacific Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 17: Asia-Pacific Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 18: Asia-Pacific Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 19: China Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 20: China Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 21: China Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 22: India Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 23: India Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 24: India Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 25: Japan Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 26: Japan Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 27: Japan Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 28: South Korea Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 29: South Korea Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 30: South Korea Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 31: Australia Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 32: Australia Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 33: Australia Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 34: Indonesia Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 35: Indonesia Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 36: Indonesia Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 37: Western Europe Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 38: Western Europe Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 39: Western Europe Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 40: UK Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 41: UK Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 42: UK Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 43: Germany Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 44: Germany Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 45: Germany Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 46: France Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 47: France Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 48: France Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 49: Italy Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 50: Italy Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 51: Italy Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 52: Spain Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 53: Spain Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 54: Spain Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 55: Eastern Europe Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 56: Eastern Europe Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 57: Eastern Europe Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 58: Russia Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 59: Russia Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 60: Russia Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 61: North America Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 62: North America Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 63: North America Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 64: USA Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 65: USA Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 66: USA Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 67: Canada Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 68: Canada Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 69: Canada Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 70: South America Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 71: South America Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 72: South America Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 73: Brazil Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 74: Brazil Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 75: Brazil Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 76: Middle East Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 77: Middle East Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 78: Middle East Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 79: Africa Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 80: Africa Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Therapy, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 81: Africa Non-Small Cell Lung Cancer (NSCLC) Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 82: Global Non-Small Cell Lung Cancer (NSCLC), Key Competitor Estimated Market Shares, 2024, Percentage (%)
    • Figure 83: Merck & Co., Inc – Financial Overview, 2020 – 2024, $ Billion
    • Figure 84: AstraZeneca plc – Financial Overview, 2020 – 2024, $ Billion
    • Figure 85: Bristol-Myers Squibb Company – Financial Overview, 2020 – 2024, $ Billion
    • Figure 86: F. Hoffmann-La Roche Ltd – Financial Overview, 2020 – 2024, $ Billion
    • Figure 87: Pfizer Inc – Financial Overview, 2020 – 2024, $ Billion
    • Figure 88: Geographic Regions Covered

    Antiobesity Market 2025-2034: Key Highlights, Growth Dynamics, and Emerging Trends

    Read More About Antiobesity Market 2025-2034: Key Highlights, Growth Dynamics, and Emerging Trends

    Emerging Trends Redefining the Antiobesity Market Landscape: Innovative Advancements In The Anti-Parkinson Drugs Market

    Read More About Emerging Trends Redefining the Antiobesity Market Landscape: Innovative Advancements In The Anti-Parkinson Drugs Market

    Top Trends Driving Innovation and Change in the Anti-Thyroid Drugs Market: Raising Awareness And Promoting Thyroid Health In The Anti-Thyroid Drug Market

    Read More About Top Trends Driving Innovation and Change in the Anti-Thyroid Drugs Market: Raising Awareness And Promoting Thyroid Health In The Anti-Thyroid Drug Market

    Market Trends Influencing Strategic Decisions in the Antivirals Industry: Innovative Oral Antiviral Treatments Enhancing Patient Compliance And Accessibility In The Fight Against Viral Infections

    Read More About Market Trends Influencing Strategic Decisions in the Antivirals Industry: Innovative Oral Antiviral Treatments Enhancing Patient Compliance And Accessibility In The Fight Against Viral Infections

    A 2025 analysis offering size estimates, growth trends and technological innovations in the live cell imaging microscopes market.

    Read More About A 2025 analysis offering size estimates, growth trends and technological innovations in the live cell imaging microscopes market.

    A 2025 market overview covering growth forecasts, treatment landscape, and key stakeholders in the isovaleric acidemia treatment market.

    Read More About A 2025 market overview covering growth forecasts, treatment landscape, and key stakeholders in the isovaleric acidemia treatment market.

    A dynamic 2025 report outlining growth drivers, pipeline innovations, and key markets in liver cancer therapeutics.

    Read More About A dynamic 2025 report outlining growth drivers, pipeline innovations, and key markets in liver cancer therapeutics.

    A 2025 analysis tracking API pricing, competitive landscape, and growth strategies in the losartan potassium active pharmaceutical ingredient market.

    Read More About A 2025 analysis tracking API pricing, competitive landscape, and growth strategies in the losartan potassium active pharmaceutical ingredient market.

    CAR-T Therapy Market 2021 - By Target Antigen (CD19, CD22, BCMA), By Application (Acute Lymphoblastic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Multiple Myeloma), And By ...

    View Report

    Central Nervous System Drugs Market 2021 - By Type (Multiple Sclerosis (MS), Anti-Psychotic, Analgesics, Anti-Parkinson Drugs, Anesthetics, Anti-Epileptics, Anti-Depressants, Other CNS Drugs), By Distribution Channel (Ho...

    View Report

    Pharmaceutical Drugs Market 2024 – By Type (Cardiovascular Drugs, Dermatology Drugs, Gastrointestinal Drugs, Genito-Urinary Drugs, Hematology Drugs, Anti-Infective Drugs, Metabolic Disorder Drugs, Musculoskeletal Disorde...

    View Report

    Oncology Drugs Market 2023 – By Type (Lung Cancer, Pancreatic Cancer, Breast Cancer, Prostate Cancer, Ovarian Cancer, Colorectal Cancer, Gastric Cancer, Kidney Cancer, Brain Tumor, Thyroid Cancer, Skin Cancer, Bladder Ca...

    View Report

    Dry Eye Medication Market 2021 - By Prescription Type (OTC Drugs, Prescription Drugs) By Drug Variation (Branded, Generic) By Type Of Product (Aqueous, Evaporative, Aqueous And Evaporative) By Distribution Channel (Hospi...

    View Report

    Respiratory Diseases Drugs Global Market Report 2022 – By Type (Anti-Asthmatics And COPD Drugs, Cough And Cold Preparations), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies/ Drug Stores), By Route Of Adm...

    View Report

    Gastrointestinal Drugs Global Market Report 2022 – By Type (Antacids, Antiulcerants, Vitamin And Minerals, Antiobesity, Antiemetics And Antinauseants, Antidiarrhoeals), By Distribution Channel (Hospital Pharmacies, Retai...

    View Report

    Hematology Drugs Global Market Report 2022 – By Type (Blood Products, Anemia And Other Blood Disorder Drugs), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Others), By Route Of Administrat...

    View Report
    Back to top
    Back to top WhatsApp icon